FDA rescinds breakthrough tag for Axsome narcolepsy med

 Axsome Therapeutics - Notified by U.S. FDA That It is Rescinding Co’s Breakthrough Therapy Designation for Its Axs-12 Product Candidate.

Axsome - FDA Btd Rescindment Due to It Approving Additional Drug Product for Treatment of Cataplexy in Narcolepsy Subsequent to Granting Axs-12 Btd.
Axsome - Does Not Currently Anticipate Any Changes to Development Plans Or Associated Timelines for Axs-12 As a Result of FDA Btd Rescindment.

https://www.cmlviz.com/stocks/AXSM/news/b/2021/07/13/axsome-therapeutics---fda-is-rescinding-co-s-breakthrough-therapy-designation-for-its-axs-12-product-candidate